Lv3
378 积分 2024-08-01 加入
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens
11天前
已完结
Precision medicine for prostate cancer: An international perspective
12天前
已完结
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer
16天前
已完结
Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of [(225)Ac]Ac/[(177)Lu]Lu-PSMA-therapy
19天前
已完结
Treatment Discontinuation in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Lutetium-177 ((177)Lu)-PSMA-617: A Retrospective Real-World Study
19天前
已完结
Correlation of Tumor Absorbed Dose with Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer Treated with (177)Lu-PSMA
19天前
已关闭
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial
19天前
已完结
Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [(177)Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
19天前
已关闭
Prompt PSA changes as a prognostic marker for response to PSMA-radioligand therapy
19天前
已完结
Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
19天前
已完结
皖公网安备34019202002308
